I find it interesting that the article on "sidedness" never mentions MSI vs MSS, or Keytruda.
Right-side tumors are more likely to be MSI-H and thus more likely to have a good response to Keytruda, while left-side MSS tumors do not. The article emphasizes drugs that affect the EGFR pathway only. That's fine for KRAS wild-type folks. It is increasingly irrelevant to the rest of us as new drugs emerge.
I think that it is likely that the information in the 2017 article is based on outdated science, just as the "survival rates" cited in various places such as Wikipedia are out of date, because they were compiled from cases that were treated before a significant number of current drugs were even available.
I'm not going to sink into gloom on the basis of that article.
F, 64 at DX CRC Stage IV (or "3 1/2" per Dana Farber consult, LOL)
3/17/18 blockage, emergency surgery, r hemicolectomy
11 of 25 nodes
5 of 5 mesentery nodes, matted
0.5 cm sub-capsular liver met removed
pT3 pN2b pM1
Neg CEA, neg BRAF, KRAS G12D, germline mut ATM
dMMR, MSI-H, Neg for Lynch
5/4/18 FOLFOX started
Added Neulasta 6/28/18
7/9/18 CT scans show no masses or enlarged nodes, 2mm indeterminate lung nodule